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Abstract
Background: Bile acid malabsorption (BAM) is one possible explanation for chronic diarrhea. BAM may be idiopathic, or
result from ileal resection or inflammation including Crohn’s disease, or may be secondary to other conditions, including
cholecystectomy, peptic ulcer surgery, and chronic pancreatitis. No “gold standard” exists for clinical diagnosis of BAM, but
response to treatment with a bile acid sequestrant (BAS) is often accepted as confirmation. The SeHCAT (tauroselcholic
[selenium-75] acid) test uses a radiolabeled synthetic bile acid and provides a diagnostic test for BAM, but its performance against
“trial of treatment” is unknown. Fibroblast growth factor 19 (FGF-19) and 7-alpha-hydroxy-4-cholesten-3-one (C4) also offer
potential new biomarkers of BAM.
Objective: This protocol describes a multicenter prospective study to evaluate the diagnostic accuracy of SeHCAT and 2
biomarkers in predicting BAM as assessed by trial of treatment.
Methods: Participating gastroenterology centers should have a minimum workload of 30 SeHCAT patients per annum. Patients
should not be pregnant, on medication that could confound follow-up, or have any severe comorbidity. All eligible patients
attending a gastrointestinal appointment will be invited to participate. On attending the SeHCAT test, blood and fecal samples
will be collected for analysis of FGF-19 by enzyme-linked immunosorbent assay and for C4 and fractionated bile acids by liquid
chromatography–mass spectrometry. A capsule containing radiolabeled SeHCAT will be administered orally and a scan performed
to measure SeHCAT activity. Patients will return on day 7 to undergo a second scan to measure percentage SeHCAT retention.
The test result will be concealed from clinicians and patients. BAS will be dispensed to all patients, with a follow-up
gastroenterologist appointment at 2 weeks for clinical assessment of treatment response and adherence. Patients responding
positively will continue treatment for a further 2 weeks and all patients will have a final follow-up at 8 weeks. The diagnostic
accuracy of the SeHCAT test and biomarkers will be analyzed at different thresholds using sensitivity, specificity, positive and
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negative predictive value, likelihood ratios, and area under the curve in a sample of 600 patients. Multivariable logistic regression
models will be used to assess the association between presence of BAM and continuous SeHCAT retention levels after adjustment
for confounders.
Results: Funding is being sought to conduct this research.
Conclusions: The SeHCAT test for diagnosis of BAM has been in common use in the United Kingdom for more than 30 years
and an evidence-based assessment of its accuracy is overdue. The proposed study has some challenges. Some forms of BAS
treatment are unpleasant due to the texture and taste of the resin powder, which may negatively affect recruitment and treatment
adherence. Trial of treatment is not as “golden” a standard as would be ideal, and itself warrants further study.
(JMIR Res Protoc 2016;5(1):e13)   doi:10.2196/resprot.4467
KEYWORDS
diagnostic test; accuracy; bile acid malabsorption; diarrhea; SeHCAT test; bile acid sequestrant
Introduction
Chronic diarrhea is a common problem and the investigation
and management of the condition places a significant burden
on health services as well as on affected patients. The suggestion
that bile acid malabsorption (BAM) can cause diarrhea was first
described by Hofmann in 1967 [1]; since then, BAM has been
identified as a possible explanation for persistent chronic
diarrhea.
Bile acids are produced in the liver, stored in the gallbladder,
and released upon eating for the digestion of dietary fat. They
are then largely reabsorbed by the terminal ileum and returned
to the liver, a process known as enterohepatic circulation. When
the reabsorption process is disrupted, excess levels of bile acids
enter the colon where they lead to increased motility and water
secretion, resulting in diarrhea.
Evidence is accumulating that BAM is more common than was
previously thought [2,3]; however, robust data on the prevalence
of BAM do not exist. Three types of BAM have been defined.
In BAM Type 1, the bile acid malabsorption results from ileal
resection, ileal disease including Crohn’s disease, or bypass of
the terminal ileum. BAM Type 2 relates to primary, idiopathic
malabsorption, whereas BAM Type 3 represents malabsorption
secondary to other conditions, including cholecystectomy, peptic
ulcer surgery, chronic pancreatitis, and celiac disease.
A diagnostic test for BAM is provided by SeHCAT
(tauroselcholic [selenium-75] acid), a radiolabeled synthetic
bile acid. The SeHCAT test is a measure of the retention of
radioactivity in the patient following administration of a capsule
containing SeHCAT. The patient is scanned with a gamma
camera 1 to 3 hours after taking the capsule and the scanning
is repeated after 7 days to measure the percentage retention of
the radiolabeled bile acid. A low SeHCAT retention level at
day 7 represents an abnormal result for the test, indicating a
positive diagnosis of BAM.
The SeHCAT test was introduced in the late 1970s; however,
despite being used for more than 30 years, much of the available
evidence is anecdotal knowledge built up over time rather than
through systematic research. A recent survey on the use of
SeHCAT in the United Kingdom provided an insight into the
frequency of use of the test and the practicalities of its
implementation in UK hospitals [4]. The study identified 73
centers using SeHCAT with a wide variation in the annual
patient workload ranging from 1 to 300 tests (mean 51; median
30). An increase in referrals since 2010 was reported in response
to demand from clinicians. Considerable variability in practical
implementation of the technique was found, alongside a wide
variation in the “normal” range of the SeHCAT percentage
retention levels used for reporting, diagnosis, and treatment.
The different approaches to definition of an abnormal result
included a single threshold value (of which <15% retention was
the most common), division into 3 categories (normal,
borderline, and abnormal), or into 4 categories (normal, mild,
moderate, and severe).
Patients with a diagnosis of BAM from a positive SeHCAT test
may be offered treatment with bile acid sequestrants (BAS),
such as cholestyramine, colestipol, and colesevelam. In general,
patients who adhere to BAS treatment respond well and rapidly
(within days) with significant reduction in bowel frequency and
improvements in their quality of life [3]. However, certain BAS
treatments are unpleasant to the patient and clear communication
between the clinician and the patient is needed to highlight the
expected benefits of treatment to ensure good adherence. Studies
have found a relationship between SeHCAT retention levels
and response to BAS treatment, with lower retention levels
associated with greater resolution of symptoms [5].
A prospective survey was conducted in 2014 by the King’s
Technology Evaluation Centre (KiTEC) to characterize the
clinical indications for referring patients for a SeHCAT test
across 38 UK centers and to describe the range of test results
and treatment pathways [6]. Patients with BAM Type 1
represented 14% of more than 700 patients tested with the
remainder split fairly equally between BAM Types 2 and 3.
Using center-defined thresholds, 51% of results were defined
as abnormal or borderline; however, only 37% of patients were
prescribed treatment with BAS. Median SeHCAT retention
levels were much lower for BAM Type 1 (2%) compared with
BAM Types 2 and 3 (18% and 17%, respectively).
The diagnostic performance of the SeHCAT test across the
range of thresholds in current use is poorly understood. There
is no established “gold standard” for the diagnosis of BAM.
However, diagnosis is sometimes made through a trial of
treatment with BAS and response to treatment with BAS offers
a potential reference standard, if taken by all patients, not just
those who the SeHCAT test suggests may be in the abnormal
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range. A review by Riemsma et al [7] identified 3 studies which
had taken this approach; however, the numbers were small
(ranging from 13 to 46 patients) resulting in wide confidence
intervals [7-10]. Specificity was more than 0.9 in all 3 studies;
in the 2 studies that used a cut-off of 8% retention, sensitivity
ranged from 0.67 to 0.95. Further research using larger samples
is needed to assess the accuracy of the SeHCAT test in
diagnosing the BAM condition as determined by response to
BAS treatment.
In addition, 2 biomarkers have shown promising results as
possible predictors of BAM, namely fibroblast growth factor
19 (FGF-19) and 7-alpha-hydroxy-4-cholesten-3-one (C4)
[11,12]. Exploration of the performance of these biomarkers as
alternative tools for discriminating between diagnoses could
potentially improve diagnostic accuracy.
This protocol describes a study that will assess the diagnostic
performance of the SeHCAT test and of 2 biomarkers in the
prediction of BAM using a positive response to treatment with
BAS as a definitive indication of the BAM condition. Improved
diagnostic accuracy for BAM should, in turn, allow treatment
of this debilitating condition to be optimized.
Objectives
The primary research objective is to investigate the diagnostic
accuracy of the SeHCAT test in providing a positive indication
of BAM among people with chronic diarrhea who are clinically
suspected of having BAM, using trial of treatment with BAS
as the gold standard.
The secondary research objectives are to investigate:
1. The continuum of results of the SeHCAT test, overall and
for different clinical populations;
2. The feasibility of using the SeHCAT test to provide an
indication of the severity of BAM (eg, mild, moderate, or
severe);
3. Adherence to treatment with BAS, overall and for different
clinical populations;
4. The diagnostic accuracy of 2 biomarker tests (FGF-19 and
C4) in predicting BAM; and
5. Whether the biomarkers can provide information on the
nature of BAM.
The tertiary research objective is, for established cut-off values,
to compare the sensitivity and specificity of the SeHCAT test
with those of the 2 biomarkers in providing a positive indication
of BAM using trial of treatment with BAS as the gold standard.
The research objectives can be translated into the following
research questions:
1. Is SeHCAT an accurate test to provide a positive indication
of BAM and what are the optimal cut-off thresholds?
2. Can different cut-off thresholds be established for the
different clinical populations under study?
3. How do the cut-off thresholds currently in use for SeHCAT
in UK centers compare with these optimal values?
4. Is SeHCAT an accurate test to grade the severity of BAM?
5. Does adherence to treatment with BAS differ for the
different clinical populations studied?
6. Can biomarkers provide an accurate test for a positive
indication of BAM?
7. Is the accuracy of biomarkers higher than that of SeHCAT
in giving a positive indication of BAM?
Methods
Type of Study
The protocol describes a multicenter prospective study. Patients
referred for suspected BAM will undergo a SeHCAT test and
be tested for the biomarkers before undergoing treatment with
BAS. Response to BAS treatment will provide a gold standard
indication of a diagnosis of BAM. The diagnostic accuracy of
the SeHCAT test and of the biomarkers will be assessed for the
prediction of BAM.
Setting
For a UK study, participating centers may be identified from
the pool of 38 centers that took part in the recent KiTEC survey.
The proposed selection criteria for the centers are (1) a minimum
workload of 30 SeHCAT patients per annum for the most recent
calendar year for which data are available; (2) agreement to
adopt a standardized SeHCAT test procedure; (3) laboratory
capacity to collect, prepare, and deliver biological samples
(blood and feces) for analysis at a remote site; and (4) formal
commitment of a consultant gastroenterologist to participate in
the study.
Study Population
Participants in the study will be adults recruited from a
population of patients attending a secondary care
gastroenterology appointment, presenting with chronic diarrhea
of unknown cause, in whom BAM is considered clinically
possible. Patients will be included if they are suspected of having
BAM Type 1 (following ileal resection, ileal disease including
Crohn’s disease, or bypass of the terminal ileum), BAM Type
2 (primary idiopathic malabsorption), or BAM Type 3
(secondary to other conditions, including cholecystectomy,
peptic ulcer surgery, chronic pancreatitis, and celiac disease).
Potential participants will be screened for eligibility using a
structured questionnaire and detailed clinical assessment.
Exclusion Criteria
Potential participants may not enter the study if ANY of the
following apply:
1. They are unable to provide informed consent;
2. They are on medication that could confound follow-up
assessment;
3. They are pregnant or they are at risk of pregnancy and do
not wish to take adequate precautions against pregnancy
for the duration of the study;
4. They have any severe comorbidity condition with less than
12 months life expectancy;
5. They are unable or unwilling to undergo a SeHCAT
procedure following the standard protocol and/or to provide
blood and fecal samples; or
6. They are unwilling to undergo a course of treatment with
BAS.
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Study Procedure and Outcome Measures
A diagram illustrating the study procedure is shown in Figure
1. All patients attending a gastrointestinal appointment at a
participating center and fulfilling the inclusion criteria will be
invited to participate in the study. Individual patient consent
will be requested at entry by the recruiting clinician. All patients
who fulfill the inclusion criteria will be given detailed
information both verbally and in the form of a patient
information sheet. During the gastrointestinal appointment,
patients will be referred by the clinicians for a SeHCAT test.
The patients will be given detailed information of all relevant
pretest and posttest dietary and medication requirements.
When the patient visits the hospital for the SeHCAT test, blood
and fecal samples will be collected before the test using standard
clinical procedures. The samples will be transferred to the local
biochemistry laboratory at each participating site, where they
will be handled by a trained biomedical scientist and prepared
for transfer to the reference laboratory. The preparation
procedure will involve taking a blood sample in a 5-mL tube
containing no anticoagulants. This sample will be centrifuged
in a standard bench-top centrifuge for 15 minutes at 3000 rpm,
and the resulting serum separated from the cells and stored at
–20°C before shipment to the central laboratory. A random fecal
sample will be collected and stored at –20°C before shipment.
The samples will be shipped on dry ice to the reference
laboratory, where the serum samples will be analyzed for
FGF-19 by enzyme-linked immunosorbent assay (ELISA), and
for C4 and fractionated bile acids by liquid
chromatography–mass spectrometry (LC-MS) using established
techniques.
The SeHCAT test will be performed in the Nuclear Medicine
Department of each participating center, following a standard
protocol, under the supervision of an Administration of
Radioactive Substances Advisory Committee (ARSAC)
certificate holder [13]. A capsule containing radiolabeled
SeHCAT will be administered to the patient orally according
to a standard procedure and considering manufacturer’s
recommendations. Patients will receive specific instructions
regarding their food intake. After 3 hours, a scan will be
performed to measure the baseline SeHCAT activity.
The patient will be requested to return to the Nuclear Medicine
Department on day 7 to undergo a second scan to measure the
retention of SeHCAT, thus completing the test. The SeHCAT
test result will be concealed from the clinician and the patient
until the 2-week follow-up appointment. On the visit to complete
the SeHCAT test, BAS will be dispensed to allow the patient
to commence treatment on the following day. BAS will be
prescribed to all patients according to a standard protocol based
on current clinical practice.
All patients will attend a follow-up appointment with the
gastroenterologist 2 weeks after the initiation of treatment with
BAS. A clinical assessment will be performed to capture the
relevant outcome measures: the patient’s adherence to treatment,
improvement of symptoms, and quality of life (QoL). The QoL
assessment will be undertaken by a research nurse trained in
qualitative methodology. The clinical assessment will determine
whether there has been a positive or negative response to BAS
treatment. A standardized definition will be agreed for the
degree of improvement in symptoms required to represent a
positive response to treatment. At the follow-up appointment,
the SeHCAT test result will be revealed to the clinician and the
patient. A positive response to treatment at 2 weeks with
evidence of treatment adherence will be used as the gold
standard that defines a diagnosis of BAM.
Patients with a negative response to treatment will stop BAS
treatment promptly (irrespective of SeHCAT test result) and
may be directed to other investigations. At this stage, blood and
fecal samples will be collected from this group for assessment
of biomarkers. Patients with a positive response to BAS
treatment (irrespective of SeHCAT test result) will continue on
BAS treatment for a further 2 weeks. For this group, a second
follow-up appointment will be performed at 4 weeks to repeat
the outcome assessment. At this second follow-up visit, blood
and fecal samples will be collected for further biomarker testing.
At 8 weeks, all patients entered into the study will be contacted
for a telephone follow-up appointment to collect final follow-up
data. Any interventions other than those included in the study
protocol will be recorded during the study period.
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Figure 1. Study procedure.
Data Collection
Relevant clinical data regarding the care pathway, diagnostic
tests, and interventions will be collected using electronic case
report forms. Patient follow-up data will be collected using a
questionnaire to be developed according to the Diagnostic
Criteria for Functional Gastrointestinal Disorders (“the Rome
criteria”) [14]. Quality of life measures will be captured using
the standard EQ-5D tool [15].
All study data will be entered onto a database by qualified
research staff and subjected to quality control checks.
Patient-identifying details will not be included in any study data
electronic files. After the closure of the study, the participating
sites will maintain all source documents, study-related
documents, and copies of the paper source documentation forms,
data query, and amendment forms in compliance with local
center policies. All source documents will be retained for a
period of 10 years following the end of the study.
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Sample size was calculated based on the 95% confidence
intervals of the sensitivity and specificity of the SeHCAT test
result in predicting true BAM as defined by response to BAS
treatment [16]. The prevalence of BAM in this population of
patients attending gastroenterology appointments with chronic
diarrhea is estimated to be approximately 50% [6]. Assuming
a minimum value of 70% for either sensitivity or specificity
[7], a sample of 600 patients (and therefore 300 true positives)
would give an acceptable 95% confidence interval of 65% to
75%. Sensitivities or specificities closer to 1 will have narrower
confidence intervals. If the assumption of 50% true positives is
incorrect, an alternative scenario of 3:1 positives to negatives
would give a 95% confidence interval of 62% to 77% around
a specificity of 70%.
Statistical Analysis
Results of the SeHCAT test (percentage retention per patient)
will be presented using suitable descriptive methods, including
frequencies, proportions, means, and standard deviations, as
appropriate. Response to BAS treatment will be presented as a
proportion of those who initiated the treatment. All descriptive
statistics will be presented with 95% confidence intervals.
The diagnostic accuracy of the SeHCAT test to provide a
positive indication of BAM compared with the gold standard
of a positive response to BAS at 2 weeks of treatment adherence
will be investigated using the receiver operating characteristic
(ROC) curves approach to compare different choice of
thresholds. Sensitivity, specificity, positive predictive value,
negative predictive value, likelihood ratios, and area under the
curve will be calculated and presented with 95% confidence
intervals. Multivariable logistic regression models will be used
to assess the association between presence of BAM and
continuous SeHCAT retention levels after adjustment for
confounders.
Similar methods will be used to assess the diagnostic accuracy
of biomarkers in the prediction of BAM. The diagnostic
accuracy of the selected biomarkers will be compared to that
of the SeHCAT test using the McNemar test for paired
proportions.
Where diagnosis of BAM is confirmed, the association between
severity of BAM (as assessed clinically at baseline) and the
continuous SeHCAT result will be investigated using appropriate
multivariable regression models taking into account prognostic
baseline variables as potential confounders.
The EQ-5D scores [15] will be derived using standard
procedures and will be used to describe the QoL of different
subgroups. The change in QoL for the SeHCAT-positive group
who respond positively or negatively to BAS will be examined
and compared using regression methods adjusting for prognostic
variables including QoL at baseline.
All analyses will be 2-sided with 5% significance level and will
be reported according to the international standards for the
reporting of diagnostic accuracy studies [17].
Ethics and Governance
Individual patient consent will be requested at entry by the
recruiting clinician. All patients who fulfill the inclusion criteria
will be given detailed information by a qualified researcher both
verbally and in the form of a patient information sheet. Patients
will be able to withdraw consent at any time during the study.
Patients may also be withdrawn from the study for medical
reasons.
Permission and approval for the proposed research will be
requested using the relevant procedures for ethical review of
studies of NHS patients in the United Kingdom. The protocol
will be reviewed by an NHS Research Ethics Committee,
overseen by the UK Health Research Authority. Local research
and development approval will also be obtained from each
participating center.
The chief investigator will be responsible for supervising the
conduct of the research and for protecting the rights, safety, and
welfare of the participants enrolled in the study. Principal
investigators will be identified at each participating site to ensure
that the research activities are conducted in an ethical manner
and in accordance with UK regulations, institutional policies,
and good clinical and research practice.
Safety and Adverse Incidents
All adverse events will be recorded and acted on by a qualified
member of staff (eg, a nurse under the supervision of the
clinician). The SeHCAT test is standard practice and is a safe
test that has been in use in the United Kingdom for more than
30 years. The SeHCAT radiolabeled synthetic bile acid is
licensed and approved for use in the United Kingdom. The test
involves exposure to a low dose of ionizing radiation. All
procedures will comply with ARSAC regulations and patients
will be given radiation protection instructions both verbally and
in writing. The BAS drugs to be prescribed are licensed and
used in standard practice, and will be used in full compliance
with the licensed indication.
Study Committees
A multidisciplinary Study Management Group will be
responsible for running the study on a day-to-day basis and will
include a manager, chief investigator, clinicians, and
statisticians. A Study Steering Committee will take major
decisions, such as changing the protocol, and will include
members who are not involved with the running of the study.
A Data and Safety Monitoring Committee will be established
and will consist of at least 3 independent members, one of whom
will be a clinical specialist and one a statistician. This committee
will be responsible for assessing recruitment data and study
conduct and the monitoring of adverse events. The research
team will include external independent members, including a
patient representative on the committees, to aid the team in
making unbiased decisions free from financial, personal, or
professional pressure.
Results
Funding is currently being sought to carry out this proposed
research.
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The SeHCAT test for diagnosis of BAM has been in common
use in UK nuclear medicine centers for more than 30 years. An
evidence-based assessment of the accuracy of the SeHCAT test
is overdue. This research is seen as a priority by the National
Institute for Health and Care Excellence in the United Kingdom
[18], who funded the recent prospective study of UK centers
[6] and the development of this protocol.
Chronic diarrhea is a debilitating condition that is not only
physically unpleasant to endure, but impacts on social
engagement and quality of life. Improving diagnostic accuracy
in the prediction of BAM should help lead to optimization of
treatment for those patients whose diarrhea is linked to this
condition and clinicians will be able to advise patients with
greater confidence.
The recent UK review [4] and survey [6] suggest that the timing
is currently optimal for conducting the proposed research.
Up-to-date contextual baseline data are available and UK centers
have recently engaged in the provision of data, with a database
of contacts available for centers, all of which should improve
the feasibility of conducting the study.
Challenges
A positive response to BAS treatment is considered here as the
gold standard for the diagnosis of BAM; a negative response
will be coded as the patient not having BAM. However, this
assumes that BAS is always effective in patients suffering from
BAM. Without further research, it is impossible to assess
whether this is a realistic claim. Similarly, it is possible that
patients may have a placebo response (ie, an improvement in
clinical symptoms even if they do not have underlying BAM).
Longer-term follow-up may help to assuage these concerns.
Some forms of BAS treatment are unpleasant and poorly
tolerated, including cholestyramine and colestipol, due to the
texture and taste of the resin powder. This may reduce both the
willingness of patients to take part in the study and adherence
to treatment once started. Recruitment may also be affected by
the fact that all patients will receive BAS regardless of whether
SeHCAT indicates any likely benefit. However, in this regard,
maintaining blindness to the SeHCAT result should help to
retain participants once they have agreed to take part. These
issues could be surmounted by using the drug colesevelam,
which is available in tablet form and is well tolerated. However,
colesevelam has not been assessed in randomized controlled
trials for the treatment of BAM and is not currently licensed in
the United Kingdom for this purpose [19].
Conducting a prospective multicenter study presents its own
challenges, which include potential variation in procedures and
in data quality between centers and the need for effective
management of centers to ensure study timelines are achieved.
To address these challenges, standardized protocols will be
developed for the administration of the SeHCAT test and the
laboratory assessment of biomarkers, and definitions will be
agreed for all clinical assessments, including those required to
assess patient eligibility and response to treatment. A consistent
approach will be developed for communicating to patients the
potential benefits as well as adverse effects of BAS treatment
to encourage optimum treatment adherence. The study manager
will be responsible for liaising with centers to ensure that agreed
procedures are observed, that patients are recruited and followed
up, and that data are complete and uploaded to the database in
a timely fashion.
Future Directions
The results from this study will need to be validated in other
populations in the future. Populations with different dietary
content, such as proportion of fiber, may react differently to the
SeHCAT test [8]. Analysis of the variation in SeHCAT results
between different centers will give an indication of the extent
to which population-specific approaches may be required.
Depending on the results found for the 2 biomarkers considered,
other biomarkers may be worth investigating as well as the
potential for combining the SeHCAT and biomarker results.
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